Strong Q1 For Chugai But Virus Uncertainties Loom
Chugai says coronavirus business impact has been minor so far but cautions this could change after a strong first quarter.
You may also be interested in...
Daily round-up of the latest coronavirus news: Trump's chloroquine mix-up, imported cases rise in China, Biogen sacks employee over China travel, Vir's Scango talks about its COVID-19 efforts, Roche's Actemra study plus COVID-19 pipeline infographic.
Entrectinib becomes first tumor-agnostic drug to be launched in Japan, its second market globally after the US, but commercial prospects will be limited given the highly specific patient population.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.